Also known as: CEPI
Moderna posted a narrower-than-expected Q2 loss, with mFLUSIVA awaiting an FDA decision and a Phase 3 norovirus trial missing early success criteria. It reaffirmed 2026 revenue growth and cash guidance.
A phase 3 trial of an mRNA H5N1 bird flu vaccine is recruiting 4,000 volunteers in the UK and US. The Moderna-sponsored study aims to assess immune responses against emerging strains as the virus continues to evolve in mammals.
The UK has begun a 4,000-volunteer H5N1 bird flu vaccine trial using mRNA technology. The study will assess safety and immune response, with CEPI providing £40m in funding.
California-based Centivax has begun dosing participants in a Phase 1A clinical trial of Centi-Flu 01, a universal influenza vaccine designed to target conserved viral regions across all flu strains. Initial data from approximately 180 participants is expected within the year.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07414524 |
VLA1553-403 Pregnancy Surveillance Study |
ENROLLING_BY_INVITATION | |
| NCT07379580 |
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa |
RECRUITING | PHASE2 |
| NCT07347002 |
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil |
ENROLLING_BY_INVITATION | |
| NCT07254702 |
Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil |
ACTIVE_NOT_RECRUITING | |
| NCT04186000 |
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola |
COMPLETED | PHASE2 |
